Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Health Catalyst (HCAT) EBITDA (2018 - 2025)

Health Catalyst (HCAT) has disclosed EBITDA for 8 consecutive years, with -$13.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA fell 29.49% year-over-year to -$13.7 million, compared with a TTM value of -$78.0 million through Sep 2025, down 7.56%, and an annual FY2024 reading of -$57.0 million, up 50.12% over the prior year.
  • EBITDA was -$13.7 million for Q3 2025 at Health Catalyst, up from -$33.5 million in the prior quarter.
  • Across five years, EBITDA topped out at -$10.6 million in Q3 2024 and bottomed at -$42.8 million in Q4 2021.
  • Average EBITDA over 5 years is -$26.4 million, with a median of -$29.7 million recorded in 2023.
  • The sharpest move saw EBITDA surged 59.56% in 2024, then plummeted 163.59% in 2025.
  • Year by year, EBITDA stood at -$42.8 million in 2021, then grew by 21.56% to -$33.5 million in 2022, then increased by 11.51% to -$29.7 million in 2023, then soared by 52.16% to -$14.2 million in 2024, then grew by 3.46% to -$13.7 million in 2025.
  • Business Quant data shows EBITDA for HCAT at -$13.7 million in Q3 2025, -$33.5 million in Q2 2025, and -$16.6 million in Q1 2025.